Christopher Lyon, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1500 Highlands Dr, Lititz, PA 17543 Phone: 717-988-0000 |
Trudie Jane Ellenberger, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 Highlands Dr, Lititz, PA 17543 Phone: 717-625-5500 |
Barry Marc Spector, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 Highlands Dr, Lititz, PA 17543 Phone: 717-988-0000 Fax: 717-782-5716 |
Clifford Catania, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 Highlands Dr, Lititz, PA 17543 Phone: 717-625-5000 |
Dr. Robert Kraus, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 Highlands Dr, Lititz, PA 17543 Phone: 717-625-5000 |
Dr. Mark Bates, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1500 Highlands Dr, Lititz, PA 17543 Phone: 717-625-5000 |
Dr. Lidio Medina, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1500 Highlands Dr, Lititz, PA 17543 Phone: 717-625-5000 |
Dr. Christine Dang, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 Highlands Dr, Lititz, PA 17543 Phone: 717-988-0000 |
News Archive
A new study provides insights on the factors that affect health-related quality of life in older adults with cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings support the importance of addressing persistent symptoms, managing comorbidities, promoting leisure-time physical activity, and addressing financial challenges.
Many research groups have recently explored human adaptation and successfully identified candidate genes to high altitude living among three major far-flung global populations: Tibetans, Ethiopians and Peruvians.
MILabs installs its industry-leading microCT system at The Center of Excellence for Translational Imaging at National Yang-Ming University in Taipei of East Asia.
A study conducted at the United States Army Research Institute of Infectious Diseases shows how a relatively simple full-length DNA vaccine against spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can elicit neutralizing antibody response in an animal model – even after a single shot with simple jet injection technique.
PanOptica, Inc., a private biopharmaceutical company focused on developing innovative ophthalmology therapies, today announced that the Company has dosed the first patient in a Phase 1/2 dose-ranging clinical trial of PAN-90806, a once-daily topical eye drop formulation of a small-molecule anti-vascular endothelial growth factor (anti-VEGF) for the treatment of neovascular eye diseases.
› Verified 8 days ago